Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Publish, Detailed Submission)

Innovation 'Elevator Pitch':
Birmingham Surgeons created endoscope-i an award-winning system that enables the viewing, recording & sharing of HD endoscopic images & videos using an iPhone/iPod. Endoscope-i works with existing endoscopes or supplied as a secured turn-key solution
Overview of Innovation:
Smartphones & tablets are becoming a central technology within clinical care systems for their high definition cameras, brilliant screens, integrated sensors and unlimited software potential.
 
Originally developed as a simple and cost effective solution to mobile endoscopic HD imaging Endoscope-i can benefit both clinicians and patients across several specialities. To date otolaryngologists, urologists, gynaecologists, orthopaedic physicians, laparoscopic surgeons and anaesthetists are some of the many specialties which benefit from using endoscopes. The superior lighting and optics allow for visualisation of 'hard to reach' areas within the human body. Endoscope-i has been involved in a number of projects globally to facilitate cost effective HD imaging and documentation.
 
The multiple award winning Endoscope-i is simple to operate and comprises an adapter to connect a medical endoscope to align with the camera of an iOS device (iPhone or iPod). The ‘e-iPro’ app allows the user to calibrate and centre the acquired image and prevents rotation allowing images to be recorded in high definition (HD) video or still images which can be shown to the patients and stored in the patient’s medical record in seconds.
 
Endoscope-i will fit any endoscope with a 32mm eyepiece, which means the possibilities are endless. A shared endoscopic view was previously the reserve of the privileged few   - where they have large expensive stacking systems - Endoscope-i makes this technology available to everyone, at a fraction of the cost and in a more convenient portable format.” 
People are surprised to hear that before Endoscope-i, clinicians relied on hand drawn sketches to update patient records.
 
NB: Data and images are currently distributed via NHS.net. Discussions are ongoing with the Information Commissioners Office to design bespoke data management protocols.
 
Endoscope-i is available to fit a range of iOS devices and has a multitude of uses which include both clinical and non clinical applications such as:-
 
Otolaryngology
HD imaging of the ear nose & throat to allow rapid and easy storage and sharing of images and videos with both patients and clinicians
 
Anaesthetics
Portable HD viewing to facilitate endoscopic fibre optic intubations available at any time
 
Veterinary
Small and large animal endoscopy from the surgery to the field using the most advanced portable camera technology
 
Engineering
Carry only one portable device for communication and sharing of images obtained on site
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
A target has been set for the NHS to become paperless by 2020. Many health trusts have facilitated this by creating their own electronic health record (EHR). However, though a transcription of the patient consultation can be typed directly into the record there is no efficient means of capturing and storing images of patient findings safely into the patient record.
 
The speciality of ear, nose and throat (ENT) examines areas of the body that are usually difficult to visualise without endoscopes. However even though there it is possible to see inside the ear nose and throat many doctors must then create a sketch of their observations for documentation.
 
To overcome this major problem, a mobile imaging solution - Endoscope-i - has been developed by a team of specialists which include engineers, software developers and practicing clinicians. The ‘Endoscope-i system’ uses the power of smart phones to quickly and safely capture images from endoscopes and store them directly into the patients EHR with the touch of a button. What’s more, patients can now share their own examination findings with their doctor or relatives to understand their condition better.
 
The images produced are of such high definition that they can be taken by doctors in primary care and then sent on to specialists in secondary care for an expert opinion, without the patient ever having to go to hospital. This saves the cost of an outpatient referral for the commissioning group, is far more convenient for the patient, reduces unnecessary journeys, frees Consultants’ clinic time, speeds diagnosis and in the long term could save millions of pounds for the NHS.
 
Initial Review Rating
3.27 (3 ratings)
Benefit to WM population:
The proposed ‘Telescopic Mobile referral service’ will allow patients to get expert opinions of their ear conditions within hours and without ever having to visit the hospital, thus saving valuable consultant time and minimising travel and inconvenience for the patient.
 
Reduced cost and greater access to services will result through the use of Endoscope-i as there is no longer a need for multiple data capture and processing devices as each Consultant can use their own iOS device to record and transfer images. Additionally, Endoscope-i will work with existing endoscopes that have a 32mm diameter eyepiece and so directly enhances the equipment’s clinical benefit.
 
In the three months of the Telescopic Referrals (Telemedicine using Endoscope-i) in North Staffordshire and Stoke and Trent, 27 referrals have been dealt with remotely from 6 GP practices. 24 of these cases were managed without referral giving an 88% success rate to referral.
 
In the West Midlands region, a new patient referral currently costs the CCG £107 compared to the remote ‘Telescopic’ referral cost of £30, a dramatic saving for the CCG. This has already saved £1,758 in referral costs alone without measuring the indirect cost benefits for patients who did not require the Telescopic referral because of the improved diagnostic ability the GP had when using Endoscope-i.
 
Reducing the need for a physical consultation will also result in transport savings and time ‘away from work’ costs for both the patient and any employer.
Current and planned activity: 
Current WMHASN funded project with Dr Ruth Chambers (Clinical Telehealth Lead at NHS Stoke-on-Trent Clinical Commissioning Group), using 15 practices from the S-O-T and North Staffordshire CCGs piloting the Telescopic Mobile Referral Service. Currently 3 months into preliminary data collection showing 30 referrals handled with Telescopic referrals powered by Endoscope-I technology. Almost 90% of patients referred avoid being sent to hospital. Cost of teleconsultation is only £30 compared to £107 for a new patient hospital consultation.
 
Endoscope-i not only provides a rapid consultant opinion for the patient but helps to deal with the excessive burden on secondary care services by keeping chronic disease and some acute ear disease management within primary care.
What is the intellectual property status of your innovation?:
No patent on product. We have full copyright of the code written for the app. Endoscope-i is a registered trademark and adapter designs fall under design copyright.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Ajith George 13/04/2016 - 07:57 Publish 5 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Software that automatically engages with stakeholders to track performance & risk and identify continuous improvement opportunities in campaigns and/or contracted out services.
Overview of Innovation:
Do you find it difficult to track and measure contract or campaign performance? Compared to well-managed contracts/campaigns, unmanaged or poorly managed contracts/campaigns can lead to costly inefficiencies, poor performance and an increase in risk.
ContractsWise is now offering its innovative, cloud-based contract management tool: ECMS, (available via the Crown Commercial Services G-Cloud Framework Agreement if required). Designed by experienced contract managers, ECMS can increase performance and savings, improve service quality, and mitigate risk, with an automatically backed-up database to prevent loss of data.
Some of ECMS’s features include:
  • A  register to record all contracts/campaigns and associated documents in a secure database
  • A dashboard that can be individually configured for each user, with information on performance and risks
  • Compatibility with any device with a web-connection, including tablets and smartphones, without the need to download additional software
  • Actively and automatically engage with stakeholders.
For those who don’t need all of ECMS’s features, there’s ECAS, an administration system that is scalable to your needs and will help improve control of information and documentation.
ECAS’s Entry Level Plan features include:
  • Searchable database of your information and documents
  • Automated reminders for important dates
  • Secure cloud storage with automated data back-up which frees up physical space
  • Archive old information
  • Online tutorials and help documents.
All of ECAS’s features are included in ECMS.
Understanding contract management and how to improve performance can be difficult, which is why ContractsWise also run an online training course: An Introduction to Contract Management, which combines theory and best practice to give you a comprehensive understanding of the subject.
For more information on the ways that ContractsWise can help please visit www.contractswise.com
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There is an increasing body of evidence that shows that organisations incur significant unplanned costs, don't achieve expected savings or service quality as a result of a lack of effective contract/campaign management.
Research by the International Association of Commercial and Contract Management (IACCM) has quantified the value of these losses at the equivalent of 9.2% of revenue.
All organisations want to achieve the maximum value for every pound spent but in the NHS this is critical. ContractsWise provides low cost tools that will enable the NHS ensure that best value is achieved, risks are identified and mitigated and opportunities for continuous improvement are identified.
A business case template is available to download for free from our website www.contractswise.com and the return on investment will include: avoidance of unplanned costs; never miss a contract termination or renewal negotiation opportunity; realise planned cost savings or revenue improvements; reduce administration time; improve internal and external stakeholder relationships; redice risks; improve compliance; improve reporting.
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Users of the NHS in the West Midlands will receive improved services and will be able to contribut eto the continuous improvement of services.
Providers of services will have greater control over their budgeted expenditure or revenue.
Current and planned activity: 
Our software has recently been adopted by Western Sussex NHS Trust.
Following a full review of software available on the market The Chartrered Institute of Procurement and Supply (CIPS) chose our software and has been operating with it since February 2015.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:

Being cloud based with minimal training required,the software can be easily scaled nationally and internationally.

Measures:

The goal is to maximise the performance and minimise the risks associated with the delivery of services by a 3rd party. Maximising performance will ensure that value for money is also maximised and will increase end user satisfaction rates. Minimising risks will reduce the possibility of unplanned costs that have not been budgetted for and will help ensure that any planned savings are actually delivered.
Users of the software will be able to continually measure performance and risk using the tools and dashboard built into the software. The users have full control over what it wants to measure so these can include quality, safety, cost and people.
ContractsWise limited will also measure the satisfaction of our customers through engagement with key stakeholders and work with them to maximise the benefits achieved by using the software in order to generate compelling case studies.

Adoption target:

Any organisation, part of an organisation or project whose measure of success relies upon the delivery of services from one or many 3rd parties.

Read more
Hide details
Noel Green 14/12/2015 - 15:53 Detailed Submission Login or Register to post comments
2.8
4
Votes
-99999
Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 16:11 Publish 3 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
We're developing an Autonomous Patient Observation System (APOS) which will automate patient observation in any environment.
Overview of Innovation:
We're a start-up creating an Autonomous Patient Observation System (APOS) which collects user data from facial expressions, physical activities, gait analysis, user habbits, agression and agitation, and so on. We're looking to provide a fully autonomous device which can gather all that data and generate reports, insights, classifications and statistical analysis.
The APOS device is the size of a can of beer, and is extremely easy to use; just register the patient, and let it work for as long as you need to. It does not use cameras, but only lazer depth sensors, and the final product will be low-cost. The APOS device aims to provide impartial, aggregated meta-data and insights, in order to make assessments and evaluations simpler, faster and more accurate.
We're focusing on a Dementia Observation System, and are also interested in frailty indexing. We will be releasing the beta product end of September, and if you would like to test one for free, please contact us.

You may find more information on our website: https://www.mechion.com
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
  • cost reduction because less workforce is needed to monitor and observe patients
  • time reduction because the task of observing and monitoring becomes automated
  • better quality of service: assessments become more accurate and decions more informed due to big data acquisition
  • product could potentially be used in homes, thereby reducing the need of placing patients in facilities
  • earlier diagnosis could be possible, remote diagnosistics and low-cost observation regardless of facilities
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
  • better quality of service received, since more data is collected on a 24/7 basis
  • reduction of costs will allow care-workers and nurses to focus on more important tasks, thereby helping the patients more
  • better and earlier diagnostics can potentially help patients sooner
  • patients could avoid hospitalisation, and be monitored from home
Current and planned activity: 
We are currently engaging international organisations (research clinics and Universities) but are looking for early adopters in the Midlands. We have interviewed and identified key problems and issues we can solve with machine learning and AI and are now moving into prototyping. We should have a beta product ready for testing end of September.
What is the intellectual property status of your innovation?:
Software and Hardware
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
4
Read more
Hide details
Alexandros Gkiokas 16/05/2018 - 13:50 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Scannable QR codes have the ability to deliver medical device operator information as a short video, when needed, and at the point of need, to reduce adverse incidents
Overview of Innovation:
VuDo (view do) Project Quick Response (QR) Codes are 2 dimensional images made up of dots which can be scanned by smart phones or tablets with a free QR code reader app. They contain over 230 times more data than the bar codes we have become used to. This property allows us to view webpages, social media, sync with an Outlook calendar, geo-locate, email, text etc.
At Heart of England NHS Foundation Trust we are using these to improve on the patient experience and staff competence by providing short learning video clips at the point of use. Devices which have been problematic in use can now have an individual code attached in a prominent position and when scanned immediately delivers a specific video of between 30 seconds to 3 minutes.
Examples of application include nebulisers and inhalers which patients can scan should they feel they need to refresh their memory on the device’s use. An important example would be their use in easing the roll out of £1 million new state-of-the-art vital signs devices across all the wards.
The VuDo QR codes are distinguished from any other codes by embedding within a camera icon, so that trained staff will readily recognise them and what they provide. The URL within each VuDo will provide data on usage for audit purposes.
VuDo works where one needs operator information without the necessity to hunt for paper based material or to log onto a computer. Other uses of VuDo include staff induction; enriching posters and leaflets; interactive hospital maps; emailing engineers of device breakdowns and more.
For cost conscious NHS Trusts the cost is minimal. If one has the video equipment then all it takes is people’s time to record, edit, upload and test the video/QR code, print off and attaching the VuDo on “infection Control” friendly stickers.
Welch Allyn Vital Signs Device
A short video clip may be viewed here http://tinyurl.com/qaa5tvm
 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The MHRA identified 25% of adverse incidents in healthcare organisations are due to poor user instructions or training. The potential costs of this to the NHS are estimated to be around £250 – 750 million. The NPSA recognised that there is a high risk of staff error due to confusion over device functionality and use.
 
Enabling clinicians to view instantly short videos, which serve as an aide memoire will:
  • reduce operator errors
  • help patients receive the correct treatment promptly
  • Reduce costs of investigating incidents
  • Reduce liabilities and costs as a result of legal action
  • Increase staff confidence and skill levels, especially for equipment not often used
 
Where devices are taken home by the patient, they can access information 24 hours a day without necessarily contacting the hospital
 
The creation costs are small. Most of the technology used is free.
Initial Review Rating
3.80 (2 ratings)
Benefit to WM population:
In essence the QR Codes make accessing any information readily available which can save time, money and improve the patient experience. Patients can feel better informed and enjoy a closer relationship with their healthcare provider. Return on investment could potentially be realised the first time a VuDo is scanned if it has a positive and direct impact on the patient experience

Each code also provides usage data for analytical purposes

Because of the low costs and limited equipment requirements the project is sustainable and transferrable. It is anticipated that use of this technolgy will also engage The Millenials (those born around 2000), who will become our future workforce and ultimatley patients.

Other applications of VuDo include staff induction; enriching posters and leaflets; interactive hospital maps; emailing engineers of device breakdowns and more.
Current and planned activity: 
This project has attracted attention within Heart of England NHS Foundation Trust. It has already created VuDos for a number of other devices and has a number commisioned for completion in the near future. Further engagement with stakeholders will identify further medical devices for inclusion in this project. The imminent launch of our "Sign up to Safety" inititative will showcase the potential of the VuDo Project.

The Academy of NHS Fab Stuff has shown interest and this project will be posted on their "wall" in due course.
 
What is the intellectual property status of your innovation?:
The technology and patents of QR codes and QR reader Apps are already established and tested. This project has just taken a broader view on where this technolgy can be best used in healthcare. We have created the term VuDo to describe the camera/QR code icon and its' ability to link directly to a video in order to differentiate it from other applications.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Simon Potter 08/01/2016 - 17:26 Publish 6 comments
4.3
4
Votes
-99999
Innovation 'Elevator Pitch':
Key challenges for Health and Care are Staff, Beds and Costs. These exacerbate, breaches, delays and overall efficiency. Our web based innovation ‘VIDIMO’ addresses all of these by bringing Health and Care organisations together 'in a virtual sense'.

Overview of Innovation:
VIDIMO - A real-time, web based platform specifically designed to target key operational challenges. Its primary audience is Health and Care professionals. At its core, VIDIMO is about reducing patient waiting times, Delayed Transfers of Care and Manual Overheads endured by front-line staff whilst improving overall visibility, efficiency, collaboration and patient flow across multiple care settings.

In essence, VIDIMO takes the Internet of Things (IoT) approach and applies it to the Care World:
 
Bringing Ambulance Trusts and Hospitals together, by delivering real-time visibility of hospital status and capacity to Ambulance Trusts and their crews to:
  • Rreduce waiting times for crews and patients
  • Reduce the £78.4m spend on private ambulance companies
  • Remove the risk of redirects altogether.
Bringing Acute hosiptals and Social Care Boroughs together by providing:
  • Real-time visibility of available beds within and beyond the organisational boundary and across multiple care settings.
  • A collaborative platform to monitor, reduce and manage Delays more effectively.
  • Reduce penalty tariffs
  • Significantly reduce manual overheads.
Bringing Social Care and other Care organisations together, allowing much greater flexibility and efficiency in locating appropriate care beds and services regardless of patient location. VIDIMO provides:
  • The mechanism for Care Homes (large or small), to make available bed assets visible to the widest possible Health and Care audience. This includes Rehab Centres, Extra Sheltered and D2A partner initiatives.
  • Provides Social Care and CCG Brokerage Teams with a single platform of visibility and management.

VIDIMO's more clever together approach is a step change from the traditional silo'd approach and provides more intelligent ways of working.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Digital health
Benefit to NHS:
Reduction in Ambulance crew wait times:
Ambulance Trusts: Lengthy A&E waits or time costly redirects from one hospital to another are costing Trusts £78.4m on private ambulance companies to help them cope with these challenges. Redirects are not only bad for crews but places additional risk on patient safety.
Number of Ambulance redirects (2017-18): 500+
Time lost in a single day by waiting Ambulance crews (Jan 2018):  800 hrs
Costs to the NHS in patient delays this winter 2017/18: - 75,000 hrs
Source: Nuffield Trust
Benefit: removal of redirects altogether.
Reduction in Ambualnce Trusts £78.4m spend on private ambulance companies
Potential reduction in ambualnce wait times meaning greater patient throughput per crew.

Reduced delays for Acute Hospitals and Social Care:
For every 1% reduction in Delays:
An additional 2000 patients would leave hospital on time.
Health and Care could reclaim 22,000 delay days and reduce their penalty tariffs by £12m.

Reduction in Manual overheads and associated costs savings.
Multiple Situation Reports, Bed management meetings and Delay Report meetings are just the tip of the iceburg when it comes to manual overheads. Add to that the effort involved in locating and appropriate care bed or service and it all adds up to a staggering 1.6m person days (equiv to an additional 9000 full-time staff) or £270m worth of care professionals time, time that could be better spend on patient. Our analysis shows that it typically takes 10-15 minutes(600-900) seconds to locate an appropriate available bed using current mothds and approaches. Using VIDIMO the task would take that length of time in seconds to locate every available bed in the region. That equates to a circa 6000% efficiency increase.
Benefit: Refocus upto 1.4m staff days back to direct patient care. CCG & Social Care brokerage teams, in fact all parties, would have unprecedented visibility of available beds across multiple care settings, with no phone calls, emails or running round in ever deceasing circles.

Reduction in the £1bn Breach/readmit penalty tariffs
Benefit:
for every 1% reduction - thousands of patients wait less time to receive appropriate level of care; reduction in NHS penalty tariffs by £10m.
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Health and Social  Care would have increaced real-time exposure to Care Home and/or care service providors regardless of size.
Increased exposure of service provision and care homes.
More efficient services from Social Care
Greater value for money.
 
Current and planned activity: 
We have initiated contact with CLAHRC, NHIR (i4i) but have yet to receive any response.
We have initiated contact with Prof. Lyndon Smith (University of the West of England) wrt 3D facial
recognition but have yet to receive any formal response.
Predictive analytics - Scheduled to meet with Kings College London.
We have initiated dialog with several AHSN's
Accepted on the Innovate UK testbed initiative (April 2018)
Reached out to all STP's
Reached out to 24 CCG's
Reached out to NIA
Reached out to ADASS national and regional
 
What is the intellectual property status of your innovation?:
We already have provision in place for our intellectual property.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Paul Rylance 02/10/2018 - 18:09 Publish 2 comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
LocumTap is a flexible software solution for the booking, management and control of temporary clinical staff within hospitals and other clinical settings with proven cost savings.
Overview of Innovation:
LocumTap is the key to managing and controlling costs of locums within Acute care, moving from using Agency to Trust staff.
The system provides a real-time two way Locum booking system consisting of: a Clinician App and Web portal for HR or Bank Staff administrators. It has been designed by clinicians within the Acute settings, who understanding the operational needs & requirements of Hospitals, their departments & their staff, with fully configurable operational flexibility built in from the onset.

Controlled and Simple Administration
LocumTap improves adherence to standard operating processes, whilst providing flexibility to facilitate the nuances of specialist departments.
It is a complete Locum booking process which reduces & simplifies the administration burden whilst providing financial insights for the control of the temporary staffing. Providing: Staff details, Vacancies, Bookings, Pay-role reports etc.

The system allows for rapid upload of bank staff to initiate the system. Staff who request to join the Bank staff, upload their personal & professional credentials via the App, prior to undertaking a Trusts HR/Bank validation /acceptance process.
Customisation - Departments can specify their requirements, such as allowing any suitably qualified staff to fill vacancies, or requiring to approve any applicants prior to dept acceptance, as well as further approving any shifts they wish to work. Allowing Clinical managers to have full confidence in the staff hired to work in their discipline/Dept.
 
Benefits for Trusts and Locums
LocumTap provides a two way operation; Either locums can browse shifts and book shifts which match their credentials on-demand or elect to fill future shifts. Thus clinicians can plan ahead, control their time and manage their finances & work-life balance. Their shift information is recorded via Paperless Timesheets - Clinicians get a digital sign-off on their app for payment processing;
or through the Bank service indicating their shift vacancies Bank Admin can also look for suitable staff from a large repository of staff who can cover shifts and directly contact them via the App dramatically minimising the hiring of Agency.

All shifts vacancies can be seen – transparency. This has meant system has proved to be liked by staff as they feel in control and it has increased vacancy shift fill rates from 60% baseline to 98.5%. This is equivalent to £750,000+ per year in cost benefit to the trust (from junior doctor shifts alone).
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
LocumTap primarily targets hospital efficiency & reduction of Agency spending, but could equally be used by smaller clinical establishments.
 
Automated and Streamlined Service
Cost Benefit
  • Reduction in Workload of HR (by reducing the administrative burden of managing the bank). Removal of inefficient and unreliable methods of communication, such an end to interrupting clinicians with numerous cold calls and emails to establish availability and to firm up bookings.
Quality
  • End to Mistakes due to human error & associated costs.
    Paperless Timesheets and pay-role outputs for finance, has meant less errors and thus  a reduction of Admin and Finance time dealing with payment queries & disputes
Morale Increased
  • Less Workload for staff bank – chasing and making changes to information
  • Minimum Admin Stress – removal/ reduction of time pressure
  • No high Staff turnover due to removal of pressure.
  • Ability to take on other productive tasks – e.g. recruitment drives
     
Recruitment Support
Cost Benefit
  • Increase of clinicians in staff pool – Flexibility, Personal Control & Transparency led to 38.5% increase of self electing Clinicians joining
  • Competition for available shifts – leading to early booked shift vacancies
  • Competitive adjustment of hourly rates – Staff selecting their own pay-rate (in Confidence)
     
 
Quality
  • Increase of Full shift coverage – leading to less HR staff stress but also increasing hospital capacity and reducing clinical / ward staff stress
  • Increasing the Choice for HR staff due to large pool of Trust staff being available
 
Reduced Reliance on Agencies
Cost Benefit
  •  Major Efficiency of spend - Cost benefit of £15,000 and £20,000 per mth for every 10% conversion of doctors and nurses respectively from agency to bank staff. Est. saving of £750,000+ per year in costs (from junior doctor shifts alone).
Quality
  • Consistent and trusted locums – Staff who know the hospital systems, procedures and protocols
  • Less opportunities for errors due to unfamiliarity with the hospital or insufficient induction
Morale
  • Greater Cross-cover for unfilled gaps in the rota – ability for staff to gain new experiences and insights
 
Real-Time Data
Cost Benefit
  • Increase in Proactive planning – Wards, Departments and Locums selecting their preferred shifts - Gamification
  • Available shifts publicised in advance of agency – Internal covered minimising need for Agency staff weeks before required (creating time to negotiate?)
Quality
  • Better Management oversight on locum activity and spend
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Although our innovation does not impact on patient safety directly, it can greatly impact of the care provided by ensure staff levels are maintained and that staff that know the hospital and the hospital them are in attendance. The evidence in the literature is patchy, although it is conventional wisdom that wards are more effective when appropriately staffed and bank staff are more efficient than external agency staff (the latter are less familiar with hospital processes, guidelines and IT).
 
The results from our current work at Chelsea-Westminster demonstrate higher staffing levels and also greater utilisation of bank staff rather than external agency staff with significant Cost savings.
 
 
The application of our technology could also be applied across Trusts with multiple sites where staff may be able to work in multiple locations or only within one or more locations. Thus this greater pool of Bank/Locum staff to draw upon should increase efficiencies and cost savings from Agency staff hire as well as reduce / remove any issues due to temporary staff not being familiar with the hospital, ward or their procedures and practices.
  
Within the Management Function it facilitates (Not covered above):
  • Better Recruitment Support - The platform has a recruitment tool to manage candidate applications - onboarding and verifying new locums.
  • Efficiencies of a Streamlined Service - Platform streamlines the entire shift booking cycle & improves adherence to operating procedures and policies.
  • Insights via Feedback and Rating System - Clinicians can be scored on their care quality, communication and punctuality. To ensure quality control and rehire-ability.
  • Informative Powerful Dashboards - Data is presented in dashboards, providing management with real time insights into all locum activity.
  • Finance / Operation Service Improvement:
    • Reduction in delayed staff payments due to removal of paper timesheets not arriving with finance in a timely fashion.
    • Reduced the time it takes to process weekly payrolls.
    • Captured escalations and virtually eliminated unwarranted and unauthorized escalations in participating departments.
    • Department managers have more visibility over the locum activity in their areas by accessing real-time and department-specific dashboards.
 
For other benefits please see previous sections.
See http://locumtap.com for further infiormation
 
Current and planned activity: 
Current Activity
Following a successfully implementation at Chelsea-Westminster Hospital Trust, we are now looking to expand across the UK and have initiated conversations with NHS trusts & STPs.
We are interested in being connected with healthcare organisations that are members of WM AHSN looking to improve on their staffing and agency operations and wish to reduce their spending.
 
Planned Activity
Thus we would like to discuss:
  • Procurement / Adoption -  LocumTap by WMAHSN Trusts, STP’s or CCGs
  • Concept Development Due to LocumTap’s flexibility & customisation, we welcome opportunities to discuss your requirements and how we may extend its capabilities for other health institutional requirements. We have plans to integrate Bank Nursing & Professions Allied to medicine and welcome input and interest in these services for your service 
What is the intellectual property status of your innovation?:
The software is copyrighted.
The system and  App is password protected and has basic encryption
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Jing Ouyang 08/09/2017 - 15:54 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 18:12 Detailed Submission 3 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Airglove is a patient warming system that gently heats the arm, raising fragile or hidden veins, making them easier and less painful to access.
 
“Up to 35% of patients require heated cannulisation due to fragile or hidden veins”
 
Overview of Innovation:
Airglove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intravenous drugs. It gently heats the patients arm up as it forces warm air through a single use double walled polythene glove.


www.greencrossmedico.com/products/airglove

Patient Solution
Airglove warming system works in just 3 minutes gently heating the patients arm to the selected temperature. Its so easy to use the nurse/practitioner simply selects the chosen temperature setting according to the patients skin type, places the patents arm in the double walled polythene glove and selects start. The patient will feel the warm air fill the glove up and vent away through a single slit perforation and after 3 minutes the machine will automatically stop with an alert sound.

Patient Clinical Considerations
With extended courses of treatment such as chemotherapy repeated cannulation is often required. Airglove can benefit fragile or hidden veins by warming the local area which gently raises the veins allowing for the insertion of the cannula. This reduces the time taken, costs and the number of attempts required which is more comfortable for both the patient and nurse/practitioner.

Patient Comfort
In addition to the benefits of easier cannulisation Airglove can help to make the patient more comfortable and relaxed with its gentle warming system with the confidence that the nurse practitioner will be able to access their veins.

Temperature Settings
The temperature can be selected to suit each skin type sensitive 31.5C, normal 35.5C or slightly heavier 38.5C with the Airglove automatically re-setting itself to normal skin type (setting 2: 35.5C) after each use. After 3 minutes the Airglove unit automatically switches off with an alert sound.

Patient Safety
No more improvisation with warm water, heat packs or even heated towels to try and gain access to patients veins which can be a Health & Safety issue.

Approved Medical Device
Airglove has taken 5 years of development, research, testing and trials by Green Cross Medico in conjunction with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust hospital. It was developed as there was a clearly defined and acknowledged need by medical professionals at The Maidstone and Tunbridge Wells NHS Trust hospital oncology department. Further trials will be starting shortly with Beatson West of Scotland Cancer Centre, Glasgow.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Patient and medicines safety / Person centred care
Benefit to NHS:
Airglove was initially developed for chemotherapy patients who have hidden or fragile veins and especially in patients who are in their 5th or 6th cycle of therapy.

The use of Airglove affords easier cannulation with fewer attempts being required (sometimes up to 6 attempts by 3 different staff can be attempted to access a difficult vein). This improved ease of access not only makes the patient’s experience far less traumatic, but ensures a better clinical outcome and saving valuable nursing/practitioner time and consumables.

Data regarding patient experience and resource savings. Patient evaluation trials at Maidstone and Tunbridge Wells Hospital NHS Trust showed 87.5% success in cannulation on first attempt with the most difficult to cannulate patients. With cannulation success, the potential cost savings on consumables are up to £50k per oncology unit, plus the nursing/practitioner’s time. Airglove is now available and is in use or on trial in over 10 hospital trusts with more waiting for demonstrations.

Improved hygiene and reduced risk of cross infection will result from the use of Airglove vs currently used methods of locally heating the arm e.g. hot towels or buckets of warm water. Only Airglove’s single use only, double walled polythene sleeve comes into direct contact with the patient’s skin. Heated air is circulated between the double wall of the sleeve and is not directly blown across the skin and so the risk of cross contamination is reduced.

Airglove can also be used for other interventions where venous access proves difficult due to fragile or difficult to find veins e.g. routine phlebotomy.

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).






 
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
The West Midlands patients and healthcare system would equally share the benefits described above for the NHS in general.

There are 13 NHS Trusts within the West Midlands having oncology departments.
 
Current and planned activity: 
Airglove is now available in the UK.

If you would like to trial Airglove for 4 weeks contact Sheena Jack 07944 519796 or email: sheena.jack@greencrossmedico.com

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).




We are also working on a further evaluation with the Beatson West of Scotland Cancer Centre, Glasgow, along with NICE Medical Technologies Evaluation Programme.


 
What is the intellectual property status of your innovation?:
Airglove is a registered Trademark.

Airglove is Patented Internationally.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:
We have not implemented in scale in any other region yet, as the product will not be available commercially until June 2018. From this point on it will be available to purchase across the West Midlands region directly from Green Cross Medico until available through NHS supply Chain.
Measures:
The success of the innovation will be measured by the uptake of Airglove throughout all 160+ oncology units throughout the UK.

This will also be determined by the cost savings to the NHS, along with patient comfort and safety, which will be assessed from the success of the patient evaluation and clinical trials.

Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum.

This could generate potential savings of £369,460 per annum to the Regional NHS.

Our trials and experience to date has demonstrated that the use of the Airglove system improves the efficiency of the nurse/practitioner, coupled to the direct consumable cost savings mentioned previously....in addition to the patient comfort benefits.

We can see from the Maidstone & Tunbridge Wells service evaluation how much of a difference it makes to the patients comfort and safety when they can be cannulated successfully on the first attempt, and to take this to the next level where all patients not just oncology can get the benefit as there are a lot of 'old and cold' as we say that are hard to cannulate and are dehydrated too.
Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum. 

This could generate potential savings of £369,460 per annum to the Regional NHS.
Read more
Hide details
Sheena Jack 10/04/2017 - 15:29 Detailed Submission 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Active+: Reducing demand for Outpatient Serivces with proactive education, activation and exercise using connected devices to self-care.
Overview of Innovation:
Active+ is an effective, evidence-based exercise class, supported by self-care technology, education and training, in a peer-to-peer supported programme developed in Huntingdonshire. The programme supports falls prevention (strength/ balance), cardiac, cancer and pulmonary rehabilitation.

In May 2017, the Activ8rlives Active+ feasibility began with cardiac rehabilitation classes inte-grating remote monitoring technology. These are being extended to people with coronary heart disease risk factors, cancer and chronic obstructive pulmonary disorder.

Active+ is a collaboration between local technology provider Aseptika Limited (Activ8rlives), Huntingdonshire District Council (HDC) Active Lifestyles, Papworth Hospital NHS Foundation Trust, Huntingdonshire Community Cancer Network (HCCN), Hunts Breathe for Life and Eastern Academic Health Science Network (EAHSN).

​See Maggie's story (Cardiac Rehabilitiation) here
​See Colin's story (Cancer Rehabilition - living with prostate cancer) here.

For further information contact
Kevin A. Auton, PhD, Managing Director, Aseptika Limited kevin.auton@aseptika.com www.activ8rlvies.com
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Active+ fills the gap between existing health and care services, with the intention of improving health outcomes and minimising expensive interventions resulting from deterioration. Evidence4 shows that people who are more activated are more likely to adopt positive behaviours and have clinical indicators within a normal range, resulting in 8% lower costs than those less activated in the fist year of support and 21% less in the second year.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Patients are educated and supported to interpret the data to enable improved understanding of their health status.
  1. Prevent unnecessary admissions as patients have access to 24/7 the COPD rapid response team as soon as there is any health deterioration for treatment to prevent unnecessary admission into hospital. The collected data is currently being analysed by Knowsley Respiratory Community Team.
  2. Technology improves patient’s confidence in managing their COPD. For patients who experience frequent infections and disease exacerbation, this can be a lifeline. In Liverpool 90% of participants would recommend to Friends and Family. 60% would be prepared to make a financial contribution of £300 to support costs.
Current and planned activity: 
Looking for Clinical Champions in Secondary Care seeking to reduce the Outpatient Workload by creation of an alternative step-down care pathway while still retaining connection with patients in a light-touch mode.
What is the intellectual property status of your innovation?:
IP owned by Aseptika Ltd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Kevin A. Auton 12/01/2017 - 12:55 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Half a million adults and children in the UK experience severe asthma symptoms despite high dose medication. Air4 offers a non pharmacological treatment of allergic disease using Temperature Laminar Airflow to reduce exposure to allergens in the bed.
Overview of Innovation:
Air4 is a unique, innovative medical device which uses Temperture Laminar Airflow (TLA) technology to protect patients with severe allergic asthma and eczema, from exposure to allergens and other airborne particles (pollens, housedust mite and animal danders etc.) that are in and around the bed at night whilst they sleep. The device has no side effects and can therefore be used for adults and children.

Air4 is installed in the bedroom alongside the bed; air is drawn in the device from the room where it is filtered and cooled to 0.5-0.8 degrees centigrade lower than the ambient temperature. As cool air is heavier than room temperature, gravity ensures the air gradually descends without an excessive breeze or draught creating the patients breathing zone; due to the density of the air in the breathing zone airborne allergens are unable to penetrate and therefore the patient sleeps in an allergen free zone.

In reducing the airborne allergens the device has shown in clinical trials that is has reduced exacerbations and the number of hosptial admissions; it has reduced day and night time symptoms in patients and improved quality of life (health related) and has shown to reduce the number of days off work/school.

Air4 has a Medical Technology Innovation briefing from NICE stating the device is clinically and cost effective.There is also an Innovation Medical Technology Overview  from Helath Improve Scotland showing the device is clinically and cost effective compared to standard treatment.

Using the Air4 in adults or children who are still symptomatic despite maximum inhaler treatment; can avoid long term side effects from oral corticosteroids as well as the regular hospital visits from other treatmenst

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Reduction in exacerbations leading to fewer hospital admissions and clinic visits
  • Reduction in use of rescue medication leading to a reduction in drug spend
  • Reduction in the number of days taken off school and work
  • Cost effective and in some circumstances cost saving treatment. Annual rental cost is offset by the economc savings in medical costs resulting in a net cost to the NHS 
  • Fulfils Care closer to home: encouraging people to live independently; provide greater choice and control over health; Reduce NHS costs and the demands for hospital resources
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Home based overnight treatment which negates the need for hospital stays.
Improvement in quality of life (HRQLS)
Improvement in sleep
Reduction in the need for rescue medication
Reduction in exacerbations and therefore hospital stays and clinic visits.
Current and planned activity: 
Current Activity: Ongoing UK trial (LASER) with results due in spring 2017 (West Midlands have 2 investigator sites)
                          Working with Innovation Nexus Greater Manchester to support clinicians use of Air4
 Current Device Use: Royal Wolverhampton, Hereford
Planned Device Use: Birmingham Childrens, Sandwell, Worcester
What is the intellectual property status of your innovation?:
IP is held by the company
Current Certification: Class 1 Medical Device; CE Marked
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Air4 is already being used in several accounts across the West Midlands with several more interested in trying the device. From a company perspective the warehouse will be informed of potential numbers and they will increase production to ensure they can meet with the increase in demand
Measures:
Overall measure of success of our innovation will be to see it accepted as a standard of care treatement for allergic disease and no longer applied for by an IFR for clinical exceptionality.
Quality Measures: Airsonett has implemented a quality management system compliant with ISO 9001, 13485 and QSR
Safety: Air4 is a CE marked class 1 medical device. As it is a non pharmacological device there are no known side effects and the device is installed,set up and removed by trained technicians.
Cost: There has been an economic analysis published in the BMJ Open Respiratory Research which found that the Air4 was a cost effective addition to standard treatment in patients with severe uncontrolled atopic asthma. These high risk patients with severe atopic asthma who use Air4 could reduce the incidence of hospitalization which could be cost saving to the NHS. Brazier et al (2015)         Airsonett® would be added to existing treatment and the average cost of long term treatment is £5.72 per day. Estimated cost of add on therapy currently used in the NHS is Omalizumab at approximately £23 per day.
The cost utility analysis estimated an incremental cost effectiveness ratio (ICER) of £8998 per quality of life adjusted year (QALY) with Airsonett®® compared to NHS standard care based on an incremental cost of £553 and a QALY gain of 0.0615. http://www.nice.org.uk/advice/MIB8/chapter/Technology-overview
People Measures:Success of the device will be measured using the following key performance indicators at 3 months for children and 6 months for adults: Improvement in the Asthma Control Test (ACT); reduction in exacerbations (compared to previous 12 months); reduction in or stopping of oral corticosteroids; Improvement in the Asthma Quality of Life Scores, adult and children (AQLQ: PAQLQ) and also improvement in sleep, work/school, and comorbid allergic disease such as eczema and/or perinnial rhinitis.
Adoption target:
Currently in WM there are 2 sites in the Laser trial (adult) and 2 sites (Paediatrics) who have patients on the device; approximately 5 additional sites across the WM with an interest. Based on the current interested sites I would estimate in the first year approximately 30 patients.
Read more
Hide details
Sarah Renshaw 03/08/2016 - 15:59 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Do you feel the frustration of having a really great idea, stonewalled by the people you’re trying to help?
WCBL is a training and coaching package we're developing to help Healthcare Transformation champions resolve the people-factor issues they face
Overview of Innovation:
What is the WCBL Package?
  • There are existing courses to address the rational, process approach to change
  • This package complement those, by addressing the human, emotional side of change.
  • We will use a people-centred approach, focusing on key aspects of how we think, communicate and build resilience as individuals.
  • The package will include various coaching methods, using traditional coaching and NLP communication tools as most appropriate.
  • The package will consist of two main elements:
    • A Digital Coaching & Training Course to bring the delegates up to an initial capability;
    • An Ongoing Support facility to help the delegates apply their newfound skills in practice and to facilitate resolution of more challenging issues.
Course Structure
The course is made up of a number of live sessions, mainly provided digitally by webinar, sandwiched with initial and final sessions face-to-face.
WCBL Toolkit: The live course elements are supplemented by an online digital ‘toolkit’ of useful video and written material, available to the delegates throughout. 
WCBL – Ongoing Support
Course ‘graduates’ will have gained new skills in resolving people-factor issues.  Ongoing support facilitates the transition to using these in practice.  This support also makes use of a mix of digital online and direct elements.

Package Aims
  • To empower delegates with understanding and rapport, so as to address human and emotional aspects of transformation programmes.
  • To build their resilience, providing the energy and motivation to resolve such issues.
What are the initial course Measurable Objectives?
  • To enable transformation ‘champions’ to resolve c.80% of the people-factor (non-functional, emotional, ‘illogical’) issues that they come across.
What are the ongoing support Measurable Objectives?
  • To enable transformation ‘champions’ to resolve nearly all of the remaining, more challenging people-factor issues that they come across.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Digital health / Innovation and adoption
Benefit to NHS:
The NHS and local councils are developing and implementing shared proposals to improve health and care in every part of England. Over the next few years, these represent the biggest national move to join up care in any major western country.” A large part of this work is underpinned by several digital health initiatives - WCBL provides the necessary skills and capabilities for NHS Transformation Teams to actually deliver what they are intended to.
Initial Review Rating
3.20 (2 ratings)
Benefit to WM population:
WIth digital health initiatives successfully in place, the WM population will have much better access to timely patient care, often in the comfort of their own home.  WCBL will allow these initiatives to succeed much more quickly and effectively.
Current and planned activity: 
Have held some discussions with healthcare agencies in the NW. 

Currently, have just completed Proof of Concept trials with with webinar taster sessions and WCBL Toolkit 'appetisers', to assess feasibility and hone the approach.  The results have been very promising, and are to be discussed with the healthcare agencies once written up.
What is the intellectual property status of your innovation?:
The coaching and training elements are, in themselves, generally available.  The specific mix of techniques and the course syllabus are Evsco Ltd commercial IPR. The webinar and toolbox platforms are commercially available (currently WebEx and Teachable).
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Andrew Evans 18/09/2018 - 19:39 Publish 3 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Catheters cause 250,000 serious infections, 3,000 deaths & up to £500m in healthcare costs a year research reports. UroShield prevents bacterial biofilm formation, increases antibiotic efficacy & decreases pain & discomfort of urinary catheter use.

Overview of Innovation:
90,000 Britons are fitted with a urinary catheter each year. Catheters are essential for a wide range of conditions that compromise the ability to empty the bladder effectively, such as prostate cancer patients and those with incontinence and neurological conditions like multiple sclerosis and spinal injury.
 
Indwelling catheters serve as an environment for bacterial attachment, biofilm formation and subsequent urinary tract infections (UTI). Biofilm formation is a thick, bacterial ‘glue’ that sticks to the surface of the catheter plastic and is highly resistant to antibiotics, making infections difficult to treat. Such catheter-acquired infections are one of the most common iatrogenic complications and may lead to increased mortality rates, extended hospital stays and increased medical costs for healthcare providers.
 
UroShield uses soundwaves to ‘shake’ away bacteria, protecting patients from painful and potentially life-threatening bladder infections. It is composed of 2 components: A disposable actuator which clips onto the external portion of the catheter and a portable battery powered driver.



The device sends out low-frequency ultrasound waves (Surface Acoustic Waves) which run longitudinally along both the inner and outer surfaces of the catheter. These surface acoustic waves prevent bacteria from docking and adhering to the catheter and subsequently prevent the formation of biofilm.
 
If there is a biofilm already present or one does form, the ultrasound waves help to break up the normally impenetrable biofilm matrix to allow access of the antibiotic to the biofilm. This increases the antibiotic efficacy by working synergistically so that patients may have a shorter course and lower dose of antibiotics.


In addition, independent studies from leading Universities have shown that the UroShield device enhances the immune systems’ ability to fight biofilm. In further studies the Uroshield device achieved a 90% reduction in the presence of common bacteria most likely to cause infection including E. coli and Staphylococcus epidermidis.
 
The action of the ultrasonic waves on the surfaces of the catheter interfere with the attachment of bacteria, prevents infections developing, reduces catheter encrustation and blockages and decreases or eliminates the need for antibiotics, reducing risk and improving patient outcomes. This in turn reduces the costs associated with indwelling catheter complications that may lead to increased medication and extended hospital stays.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Innovation and adoption
Benefit to NHS:
Reducing health care-associated infections (HCAIs) remains high on the Government’s
safety and quality agenda and in the general public’s expectations for quality of care.
 
Patients with invasive devices such as urinary catheters are at a greater risk of developing a HCAI (NICE, 2012). In addition to increased costs, each one of these infections means additional use of NHS resources, greater patient discomfort and a decrease in patient safety.
 
UroShield is a breakthrough device to prevent or treat catheter-related trauma.
 

 
Once the urinary catheter has been placed into the patient’s bladder, the actuator is clipped on the extracorporeal part of the catheter and the device is activated. UroShield harnesses the known therapeutic effects of ultrasound such as tissue healing and muscle relaxation to significantly decrease catheter-associated pain and discomfort. This is extremely easy for nurses to use and maintain, with a simple clip around the catheter to be changed monthly and disposed of in standard waste.
 
UroShield could have huge implications for reducing A&E admission rates as 224,670 admissions for UTIs were reported in 2009 and 2010 and since then numbers have continued to increase, with 43-56% of all UTIs being associated with indwelling. Between 2013/2014, the NHS spent £434 million treating 184,000 hospital admissions for a UTI.
 
UroShield could play a key role in achieving CQUIN targets for CAUTI rates and the reduction in E. coli Bloodstream Infections through the initial prevention of infection.
 
E. coli is one of the main pathogens responsible for causing UTIs and CAUTI, of which Gram-negative CAUTIs are often a source of bacteraemia. E. coli account for 55% of all BSIs and of these UTIs are responsible for 45% of E. coli BSIs. E. coli BSIs have increased by 20% over the last five years and the trend is still rising, which is of grave concern.
 
E. coli BSI are therefore a huge patient safety issue and are set to cost the NHS £2.3 billion by 2018. These contributed to over 5,500 NHS patient deaths in 2015 and there is £45 million quality premium which is incentivised by Ruth May to reduce healthcare associated Gram-negative BSIs by 50% across the NHS by 2021. The goals are to: prevent the need for antibacterial prescription, to reduce the dose or length or antibiotics as a minimum, and to reduce hospital admissions and HCAIs.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Over 1 million patients a year have a catheter for a short time while in hospital & those using them at home for longer periods have them changed every 3 months & infections can be missed between changes.
 
An untreated urinary tract infection (UTI) may spread to the kidney, causing more pain & illness & lead to sepsis, a life-threatening reaction to an infection.
 
Long-term catheterisation carries a significant risk of symptomatic UTI, which can lead to serious complications such as bloodstream infections (NICE 2012). The diagnosis of a CAUTI increases the use of antibiotics which will increase the burden & development of antimicrobial resistance (DH, 2007).
 
Recurrent lower UTIs have a detrimental effect on patients quality of life. Patients experience a psychological burden because they live with the anxiety of sudden acute episodes. The resulting social handicap is known to induce feelings of self-devaluation or culpability, which can lead to clinical symptoms of depression.
 
UroShield could protect thousands of patients from painful & potentially life-threatening bladder infections reducing the psychological burden & anxiety patients experience.
 
The innovation is currently being trialled in NHS hospitals with leading urologists including a consultant & surgeon at the Royal Marsden in London describing the device as ‘game-changing’.
 
Uroshield comprises an electronic driver (8-hour battery life) weighing 5g & a disposable clip that fits around the catheter tube, the driver transmits continuous ultrasound waves to the clip via a small cable. The rechargeable device can be switched on & off & a small screen on the driver indicates power supply & battery life.
 
Clinical trials have shown the acoustic sound waves generated by the UroShield device along the urinary catheter result in a significant decrease in catheter-associated pain & discomfort.
 
Click the image below to read the full article.


 
UroShield significantly reduces bladder washouts in catheterised patients & thus could reduce visits from district nurses to generate significant cost & time savings. For example, one patient required daily bladder washouts & since UroShield no longer requires any at all. Patients can have greatly extended catheter life, reducing the frequency of catheter change & maintenance & nurse callout time associated with this. Alongside freeing time & resources, UroShield could also assist Infection Prevention Nurses in achieving CQUIN targets based on catheter-associated infection rates.
Current and planned activity: 
We are speaking with over 80 primary and secondary care sites with regards to UroShield. We currently have 6 NHS sites evaluating UroShield in small scale patient service evaluations alongside a double-blind randomised controlled trial producing positive data proving the efficacy of UroShield.
 
We are also working to provide Health Economic Data which will further support the use of UroShield across various healthcare settings. To support this we are looking to work with a NHS partner in the West Midlands to undertake a small-scale (service) real-life evaluation of UroShield to demonstrate patient and fiscal benefits of using the device.
 
UroShield can help you to support the delivery of the national ‘reducing the impact of serious infections (Antimicrobial Resistance and Sepsis’ CQUIN by creating a new, improved pattern of care for patients, reducing their risk of painful and potentially life-threatening bladder infections.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Alex Ackernley 05/07/2018 - 09:41 Publish 4 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
The Hydrant is a novel and effective solution of proviiding fluids to those patients with poor mobility or requiring flat-bed rest. it consists of a bottle and drinking tube that can be postioned to allow the patient to independently consume fluids.
Overview of Innovation:
 Within the NHS dehydration remains a significant problem with recent reports suggesting it may affect as many as one in seven hospital patients and cost the NHS £1 billion a year. The majority of hydration in secondary care, is reliant on patients’ independent consumption of fluids.One way to improve hydration amongst these groups of patients is to increase accessibility of fluids using drinking aids. These aids encompass a broad range of products from insulated mugs that maintain drinks at the appropriate temperature to more complex devices designed for patients who find it difficult to drink from standard vessels. it consists of a bottle with an adjustable, self-supporting drinking tube with a bite valve that allows patients to draw fluid from the device. The device has won design awards and offers a sensible solution to providing fluids for those patients with poor mobility or physical capacity, or otherwise confined to flat-bed rest. The bottle has been trialled on the Neurosurgery ward at UHB and was greeted favourably by staff and those patients offered it. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
Within the NHS dehydration remains a significant problem with recent reports suggesting it may affect as many as one in seven hospital patients and cost the NHS £1 billion a year (Good, Richard 2014) with elderly patients particularly susceptible due to their diminished thirst sensation and changes in kidney function (Hooper 2014).  The majority of hydration in secondary care is reliant on patients’ independent consumption of fluids.  The act of drinking appears a straightforward response to a physiological need yet it is in fact a complex behaviour determined by a variety of factors and their interactions (Koster 2009) including physical, psychological, and environmental influences (Kenney 2001). In the ward environment patients rely on the support of health care providers and yet staff frequently report a number of barriers to performing hydration care with insufficient time as a key barrier amongst them (Simmons 2001; Mentes, chang 2006). This can leave patients with limited movement, cognitive ability or higher clinical dependency particularly vulnerable to dehydration. One way to reduce this risk is to increase accessibility of fluids using drinking aids such as the Hydrant. 
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
As above
Current and planned activity: 
The primary issue with its upatke within UHBFT was the availability of the device. Staff on wards where patients would benefit from its use were unable to procure the device.
We propose that WMAHSN facilitate a series of meetings with key staff involved in procurement at the hospital to improve the supply and availability of the bottle.
Once the bottle is more freely available we propose to raise awareness of its availability with staff on the relevant wards.
 
What is the intellectual property status of your innovation?:
Licensed product of Hydrate for Health Ltd,
http://www.hydrateforhealth.co.uk/our-products/the-hydrant/
 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Ian Litchfield 03/11/2017 - 13:18 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Cladribine is a new oral therapy for the treatment of highly active Multiple Sclerosis (MS). It is effective in reducing relapses and can substantially reduce the administration and monitoring burden associated with other therapies currently in use.
Overview of Innovation:
The MS Society estimates that there are approximately 107,000 people with MS in the UK, and that each year 5,000 people are newly diagnosed with the condition. This means around one in every 600 people in the UK has MS. MS is between two to three times more common in women than men.
 
Multiple sclerosis is a chronic and debilitating autoimmune disorder of the central nervous system.  In Multiple Sclerosis, the body’s own immune cells mistakenly attack the myelin that surrounds nerve fibres, leading to nerve damage.
 
Cladribine is a small oral molecule, developed by Merck, that selectively reduces the number and activity of these immune cells (B and T lymphocytes) and modulates cytokines. There is only a transient and relatively small effect on the innate immune cells such as neutrophils.
 
Cladribine Tablets have been investigated in 4 main phase II/III studies in MS. In a Phase III study (CLARITY), 3.5mg/kg Cladribine Tablets over 2 years (n = 433) with significantly reduced annualised relapse rates (ARR) by 77.8% in patients with Relapsing Remitting Multiple Sclerosis compared with placebo (n = 437) (p<0.001).
 
A phase IIIb extension study (CLARITY EXT) confirmed that the initial 2 year treatment with 3.5 mg/kg Cladribine Tablets was effective in reducing the frequency of relapses in years 3 and 4 by 75.6%.
 
A post hoc analysis of the CLARITY data, which focused on a subgroup with High Disease Activity, provided a consistent treatment effect on relapses for Cladribine Tablets compared with placebo.
 
The safety profile of Cladribine Tablets has been thorougly investigated in the 4 main phase II/III clinical studies and an ongoing PREMIERE registry.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Cladribine has the potential to deliver high efficacy without continuous suppression of the immune system;this results in a manageable safety and tolerability profile and low administration and monitoring burden.
     
  • Cladribine tablets are an oral therapy that selectively targets the immune system to produce effective disease control for up to 4 years with only 10 days of treatment per year for the first 2 years.
     
  • Cladribine tablets broaden treatment options for commissioners, clinicians and patients with highly-active MS.
     
  • Cladribine has the potential to substantially reduce the overall volume of administration and monitoring and of associated costs.
In addition, in many areas of England, MS specialist nurses (who bear much of the responsibility for administration and monitoring) are currently working at or above their patient capacity. The use of Cladribine has the potential to substantially free up this specialist nurse resource

CLADRIBINE IS THE ONLY MS THERAPY WHICH HAS RECEIVED A 'RAPID UPTAKE' DESIGNATION FROM THE ACCELERATED ACCESS COLLABORATIVE.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The West Midlands Region has approximately 9,360 MS patients of which 1,363 are
estimated to be on MS treatments for highly active MS.
 
If these 1,363 patients had been treated with Cladribine as opposed to current therapies, an estimated saving of £18.1 million could be made over a 4 year period.
The above figures do not include the 20% VAT which is charged on MS therapies which are dispensed and administered in hospital Trusts (mainly infused MS therapies).

In addition,the availability of an oral alternative reduces the need for patients to attend hospital Trusts which may be located substantial distances from where the patients live.
Current and planned activity: 
Current activity
An agreement has been made with NHS England which provides an up front discount and also a rebate if the product is discontinued and replaced by another MS therapy during the expected 4 yr treatment window. 
NICE approval occured on 6th Dec.2017( TA 493 ).
Planned activity
MS treatments are traditionally prescribed by MS specialists based in hospital Trusts. However, the bulk of the costs of administration and monitoring are borne by CCGs.
Increases in the volumes of monitoring of specialised medicines are also creating service and governance challenges in some localities.
 
There is therefore a need to move from taking a purely secondary care to a cross-sector perspective when considering which treatments are most clinically and economically appropriate.
 
The support of West Midlands AHSN would therefore be very much welcomed in facilitating discussions between the relevant service stakeholders and to ensure a cross-sector perspective.
What is the intellectual property status of your innovation?:
The product license holder in the UK is Merck Serono Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Richard Lomas 27/06/2017 - 13:14 Publish 1 comment
0
0
Votes
-99999

Active Campaigns